Ionis Pharmaceuticals Reports Setbacks in Key Programs Amid U.S. Healthcare Conference

Ionis Pharmaceuticals (IONS), a biopharmaceutical company with a market cap of $9.15 billion, presented its outlook at the Wells Fargo Healthcare Conference on September 10, 2024, amid mixed results in its therapeutic programs and revenue challenges. The company reported a year-over-year decline in revenue to $874 million, a 7.4% drop, and a negative gross profit margin of –6.9%, reflecting ongoing financial pressures. Loss per share stood at $3.46, though analysts anticipated a 52% upside from current share prices, with a consensus range of $54 to $105 per share.